May 22, 2020   SOURCE: PR NewsWire

Global Cancer Antibody Drug Conjugate Market: A US$13 Billion Opportunity

DUBLIN, May 22, 2020 /PRNewswire/ -- The "Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This report offers comprehensive clinical and non clinical insight on the recent trends and the opportunities that the market has been experiencing at a regional and at global level. The cancer antibody drug conjugate market has been witnessing tremendous growth and offers unexplored potential to pharmaceutical companies involved in development in the anti cancer therapeutics market. This new drug class is widely accepted in the form of monotherapy as well as combinational therapy among Breast Cancer, Acute Leukemia and Lymphoma patients. In addition to the various strategies that have been employed by the major key players of the market, the report also delivers information regarding the achievements, valuable highlights and all the progressive compilations that have been made in the market.

As per report findings, cancer antibody drug conjugates will experience tremendous success in the upcoming years in both the research and market segments. The continuous success of the approved cancer antibody drug conjugates and presence of many new antibody drug conjugates in the clinical pipeline is indicating a very bright future for this market. The challenges for this market are very few, which can be easily overcome in a short period of time and the driving factors such as unmet medical demand and high prevalence of cancer, are continuously boosting market growth. Antibody drug conjugates will occupy a dominant share in overall oncology market and it will emerge as most prominent cancer therapeutic segment.

Key Report Highlights:

    --  Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs
    --  Marketed Cancer Antibody Drug Conjugate: 9 Drugs
    --  Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026
    --  Majority of Drug Trials Are For Second Line Therapy Or Greater
    --  USA Dominates Cancer ADC Clinical Trials Landscape: > 180 Drugs
    --  Tubulin Modulators Dominates Cancer ADC Trials: > 60 Drugs
    --  Sales, Market Opportunity, Clinical Trials Graphs: > 100 Graphs

Key Topics Covered:

1. Introduction to Antibody Drug Conjugates (ADCs)

2. Evolution of Antibody Drug Conjugates
2.1 Advancements in ADCs
2.2 Components of ADCs

3. Antibody Drug Conjugates - Mechanism of Action
3.1 Antigen-Antibody Interaction
3.2 Release of Payload
3.3 Mechanism of Cytotoxicity

4. Need of Antibody Drug Conjugates

5. Role of ADCs in Cancer Management
5.1 Breast Cancer
5.2 Leukemia
5.3 Lymphoma
5.4 Other Cancers

6. Antibody Drug Conjugate Market Analysis
6.1 Overview
6.2 Current Market Scenario
6.3 ADCs Market Segmentation


7. Global - Cancer Antibody Drug Conjugate Market Insights
7.1 US
7.2 Europe
7.3 Japan
7.4 China
7.5 India
7.6 South Korea

8. Antibody Drug Conjugates - Availability, Dosage & Price Analysis
8.1 Mylotarg (Gemtuzumab ozogamicin)
8.2 Adcetris (Brentuximab vedotin)
8.3 Kadcyla (Trastuzumab emtansine)
8.4 Besponsa (Inotuzumab ozogamicin)
8.5 Lumoxiti (Moxetumomab pasudotox)
8.6 Polivy (Polatuzumab vedotin)
8.7 Enhertu (Fam-Trastuzumab Deruxtecan-Nxki)
8.8 Padcev (Enfortumab Vedotin)

9. Antibody Drug Conjugates - Sales Insight
9.1 Kadcyla
9.2 Adcetris
9.3 Polivy

10. Antibody Drug Conjugates - Clinical Pipeline Insight 2020 - 2026
10.1 By Phase
10.2 By Indication
10.3 By Company
10.4 By Patient Segment
10.5 By Country
10.6 By Mechanism of Action

11. Global Cancer Drug Conjugates Clinical Pipeline By Company, Indication & Phase
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-0
11.5 Phase-I
11.6 Phase-I/II
11.7 Phase-II
11.8 Phase-II/III
11.9 Phase-III
11.10 Preregistration
11.11 Registered

12. Marketed Cancer Drug Conjugates Clinical Insight
12.1 Adcetris
12.2 Mylotarg
12.3 Junovan/Mepact
12.4 Kadcyla
12.5 Besponsa
12.6 Zevalin/ Zevamab
12.7 LUMOXITI
12.8 OncoScint CR/OV
12.9 Enhertu

13. Global Cancer an Antibody Drug Conjugates Market Dynamics
13.1 Favorable Parameters
13.2 Challenges for Antibody Drug Conjugates Market

14. Antibody Drug Conjugates Market - Future Outlook

15. Competitive Landscape

    --  Astellas Pharma
    --  AstraZeneca
    --  Bristol Mayer Squibb
    --  Celldex Therapeutics
    --  Genentech
    --  Heidelberg Pharma
    --  Immunogen
    --  Mersana Therapeutics
    --  Oxford BioTherapeutics
    --  Pfizer
    --  Progenics Pharmaceuticals
    --  Roche
    --  Seattle Genetics
    --  Synthon
    --  Takeda Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/zj5e2

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-cancer-antibody-drug-conjugate-market-a-us13-billion-opportunity-301064361.html

SOURCE Research and Markets